Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2011-2014

ABSTRACT

Tau pathology and tangles have been associated with cognitive dysfunction causing neurodegeneration. AD, the most abundant tauopathy is characterized by amyloid plaques and tau tangles. An abundance of tau inclusions, in the absence of amyloid deposits, defines Pick's disease (frontotemporal lobar degeneration), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and other diseases including frontal atrophy associated with cognitive clinical dysfunction of frontal dysexecutive syndrome, progressive nonfluent aphasia and semantic dementia as recently reviewed (Gozes 2010). It is the investigators aim to follow other protein expression [as per recent publications (Marksteiner et al., 2011)] in blood and CSF samples from those tauopathies. Significance: Results should establish the possibility of using tau and other proteins as markers for early detection and disease progression in FTD, also in comparison to Alzheimer's disease (AD). Detailed Description Assessing biomarkers in Alzheimer's disease and frontotemporal dementia 1. Specific Aims To enhance the field of biomarker recognition and facilitate preventative and personalized medicine we are now posing the following question, does the Israeli patient population present similar plasma protein profile as described before for other populations (Marksteiner et al., 2011). Studies will be carried out by RNA transcript quantification, quantitative real time polymerase chain reaction (blood cells and CSF) and immunochemical detection at the protein level (CSF and serum). 2. Methods: Lymphocytes: Human lymphocytes are isolated from 10 ml of venous blood using the Ficoll Paque method (de Rock and Taylor 1977; McCauley and Hartmann, 1982), for RNA extraction and determinations we shall follow-up the methods described in our manuscripts (Dresner et al., 2011). Blood plasma and serum will be prepared as outlined in www.peoimmune.com. Protein quantitation will be carried out using the Tri reagent (Sigma) which allows for simultaneous preparation of RNA, DNA and protein and plasma immunodepletion and albumin depletion kits from Sigma. Protein quantification: this will be carried out on cellular proteins and also on plasma proteins by SDS-polyacrylamide gel electrophoresis, followed by western analysis. CSF samples will be collected through a spinal needle inserted into the L4-L5 or L3-L4 vertebral space with the subject in the lateral decubitus position. One ml of CSF derived from each patient will be immediately immersed in ice, with subsequent maintenance at -70 degrees C (or in dry ice during shipping) until the time of the assay. Half ml of each CSF sample will be concentrated by lyophilization in a Speed-Vac (Holten, Gydevang, Denmark) to about 0.1ml. CSF protein immunoblotting will be performed using a similar methodology as described above [and see also(Kozlovsky et al., 2004)]. Protein expression will be analyzed by western blots (Shiryaev et al., 2010). Number of patients: We estimate that about 30 patients with Alzheimer's disease, 20 patients with frontotemporal dementia and 20 controls will be included. Professor Aharon-Peretz will evaluate patients with suspected Alzheimer's disease and frontotemporal dementia and include patients at various disease stages in a stratified manner (mild, moderate and severe). All patients will have signed an informed consent form, as per Helsinki guidelines. Clinical evaluation will include: physical and neurological evaluation. All patients will be asked to donate 50 ml blood and selected patients will undergo lumber puncture. The lumber puncture will be performed with the neurological work up. Professor Gozes will coordinate the scientific aspect of the study. Study coordinators: Scientific: Professor Illana Gozes, PhD, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors; Director, The Adams Super Center for Brain Studies, Tel Aviv University: igozes@post.tau.ac.il Clinical material: Professor Judith Aharon-Peretz, MD, Head of "Cognitive Neurology Unit" Rambam Rambam-Health Care Campus, Haifa, Israel More... »

URL

https://clinicaltrials.gov/show/NCT01403519

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3120", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Tau pathology and tangles have been associated with cognitive dysfunction causing neurodegeneration. AD, the most abundant tauopathy is characterized by amyloid plaques and tau tangles. An abundance of tau inclusions, in the absence of amyloid deposits, defines Pick's disease (frontotemporal lobar degeneration), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and other diseases including frontal atrophy associated with cognitive clinical dysfunction of frontal dysexecutive syndrome, progressive nonfluent aphasia and semantic dementia as recently reviewed (Gozes 2010). It is the investigators aim to follow other protein expression [as per recent publications (Marksteiner et al., 2011)] in blood and CSF samples from those tauopathies. Significance: Results should establish the possibility of using tau and other proteins as markers for early detection and disease progression in FTD, also in comparison to Alzheimer's disease (AD).\n\nDetailed Description\nAssessing biomarkers in Alzheimer's disease and frontotemporal dementia 1. Specific Aims To enhance the field of biomarker recognition and facilitate preventative and personalized medicine we are now posing the following question, does the Israeli patient population present similar plasma protein profile as described before for other populations (Marksteiner et al., 2011). Studies will be carried out by RNA transcript quantification, quantitative real time polymerase chain reaction (blood cells and CSF) and immunochemical detection at the protein level (CSF and serum). 2. Methods: Lymphocytes: Human lymphocytes are isolated from 10 ml of venous blood using the Ficoll Paque method (de Rock and Taylor 1977; McCauley and Hartmann, 1982), for RNA extraction and determinations we shall follow-up the methods described in our manuscripts (Dresner et al., 2011). Blood plasma and serum will be prepared as outlined in www.peoimmune.com. Protein quantitation will be carried out using the Tri reagent (Sigma) which allows for simultaneous preparation of RNA, DNA and protein and plasma immunodepletion and albumin depletion kits from Sigma. Protein quantification: this will be carried out on cellular proteins and also on plasma proteins by SDS-polyacrylamide gel electrophoresis, followed by western analysis. CSF samples will be collected through a spinal needle inserted into the L4-L5 or L3-L4 vertebral space with the subject in the lateral decubitus position. One ml of CSF derived from each patient will be immediately immersed in ice, with subsequent maintenance at -70 degrees C (or in dry ice during shipping) until the time of the assay. Half ml of each CSF sample will be concentrated by lyophilization in a Speed-Vac (Holten, Gydevang, Denmark) to about 0.1ml. CSF protein immunoblotting will be performed using a similar methodology as described above [and see also(Kozlovsky et al., 2004)]. Protein expression will be analyzed by western blots (Shiryaev et al., 2010). Number of patients: We estimate that about 30 patients with Alzheimer's disease, 20 patients with frontotemporal dementia and 20 controls will be included. Professor Aharon-Peretz will evaluate patients with suspected Alzheimer's disease and frontotemporal dementia and include patients at various disease stages in a stratified manner (mild, moderate and severe). All patients will have signed an informed consent form, as per Helsinki guidelines. Clinical evaluation will include: physical and neurological evaluation. All patients will be asked to donate 50 ml blood and selected patients will undergo lumber puncture. The lumber puncture will be performed with the neurological work up. Professor Gozes will coordinate the scientific aspect of the study. Study coordinators: Scientific: Professor Illana Gozes, PhD, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors; Director, The Adams Super Center for Brain Studies, Tel Aviv University: igozes@post.tau.ac.il Clinical material: Professor Judith Aharon-Peretz, MD, Head of \"Cognitive Neurology Unit\" Rambam Rambam-Health Care Campus, Haifa, Israel", 
    "endDate": "2014-01-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01403519", 
    "keywords": [
      "Alzheimer's", 
      "frontotemporal dementia", 
      "tau pathology", 
      "tangle", 
      "cognitive dysfunction", 
      "neurodegeneration", 
      "AD", 
      "tauopathies", 
      "Amyloid Plaque", 
      "abundance", 
      "inclusion", 
      "absence", 
      "Pick's", 
      "disease", 
      "frontotemporal lobar degeneration", 
      "progressive supranuclear palsy", 
      "corticobasal degeneration", 
      "atrophy", 
      "dysfunction", 
      "syndrome", 
      "aphasia", 
      "investigator aim", 
      "protein expression", 
      "recent publication", 
      "blood", 
      "CSF sample", 
      "significance", 
      "possibility", 
      "tau", 
      "protein", 
      "marker", 
      "early detection", 
      "disease progression", 
      "comparison", 
      "Alzheimer Disease", 
      "Assessing", 
      "Biological Marker", 
      "dementia", 
      "Specific aim", 
      "recognition", 
      "medicine", 
      "patient population", 
      "population", 
      "RNA transcript", 
      "Real-Time Polymerase Chain Reaction", 
      "blood cell", 
      "protein level", 
      "CSF", 
      "serum", 
      "method", 
      "lymphocyte", 
      "human lymphocyte", 
      "venous blood", 
      "rock", 
      "RNA extraction", 
      "determination", 
      "manuscript", 
      "plasma", 
      "quantitation", 
      "reagent", 
      "sigma", 
      "preparation", 
      "RNA", 
      "DNA", 
      "immunodepletion", 
      "depletion", 
      "protein quantification", 
      "cellular protein", 
      "plasma protein", 
      "SDS-polyacrylamide gel electrophoresis", 
      "Western analysis", 
      "needle", 
      "vertebral", 
      "patient", 
      "ice", 
      "subsequent maintenance", 
      "dry ice", 
      "assay", 
      "half", 
      "Freeze Drying", 
      "speed", 
      "Denmark", 
      "immunoblotting", 
      "similar methodology", 
      "Western Blotting", 
      "control", 
      "disease stage", 
      "consent form", 
      "guideline", 
      "clinical evaluation", 
      "selected patient", 
      "puncture", 
      "scientific aspect", 
      "study coordinator", 
      "PhD", 
      "chair", 
      "growth factor", 
      "brain study", 
      "Tel Aviv", 
      "clinical material", 
      "MD", 
      "head", 
      "neurology", 
      "Haifa", 
      "Israel"
    ], 
    "name": "Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01403519"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00011.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.12136.37", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413731.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2011-07-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1002/jnr.22431", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012508219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0022-1759(77)90120-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016178552"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.euroneuro.2010.06.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023497938"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0022-1759(82)90301-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043921516"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00702-003-0127-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047259725", 
          "https://doi.org/10.1007/s00702-003-0127-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00702-003-0127-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047259725", 
          "https://doi.org/10.1007/s00702-003-0127-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.neurobiolaging.2009.03.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047358633"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/156720510793611628", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069189008"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01403519"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01403519'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01403519'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01403519'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01403519'


 

This table displays all metadata directly associated to this object as RDF triples.

148 TRIPLES      16 PREDICATES      128 URIs      114 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01403519 schema:about anzsrc-for:3120
2 schema:description Tau pathology and tangles have been associated with cognitive dysfunction causing neurodegeneration. AD, the most abundant tauopathy is characterized by amyloid plaques and tau tangles. An abundance of tau inclusions, in the absence of amyloid deposits, defines Pick's disease (frontotemporal lobar degeneration), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and other diseases including frontal atrophy associated with cognitive clinical dysfunction of frontal dysexecutive syndrome, progressive nonfluent aphasia and semantic dementia as recently reviewed (Gozes 2010). It is the investigators aim to follow other protein expression [as per recent publications (Marksteiner et al., 2011)] in blood and CSF samples from those tauopathies. Significance: Results should establish the possibility of using tau and other proteins as markers for early detection and disease progression in FTD, also in comparison to Alzheimer's disease (AD). Detailed Description Assessing biomarkers in Alzheimer's disease and frontotemporal dementia 1. Specific Aims To enhance the field of biomarker recognition and facilitate preventative and personalized medicine we are now posing the following question, does the Israeli patient population present similar plasma protein profile as described before for other populations (Marksteiner et al., 2011). Studies will be carried out by RNA transcript quantification, quantitative real time polymerase chain reaction (blood cells and CSF) and immunochemical detection at the protein level (CSF and serum). 2. Methods: Lymphocytes: Human lymphocytes are isolated from 10 ml of venous blood using the Ficoll Paque method (de Rock and Taylor 1977; McCauley and Hartmann, 1982), for RNA extraction and determinations we shall follow-up the methods described in our manuscripts (Dresner et al., 2011). Blood plasma and serum will be prepared as outlined in www.peoimmune.com. Protein quantitation will be carried out using the Tri reagent (Sigma) which allows for simultaneous preparation of RNA, DNA and protein and plasma immunodepletion and albumin depletion kits from Sigma. Protein quantification: this will be carried out on cellular proteins and also on plasma proteins by SDS-polyacrylamide gel electrophoresis, followed by western analysis. CSF samples will be collected through a spinal needle inserted into the L4-L5 or L3-L4 vertebral space with the subject in the lateral decubitus position. One ml of CSF derived from each patient will be immediately immersed in ice, with subsequent maintenance at -70 degrees C (or in dry ice during shipping) until the time of the assay. Half ml of each CSF sample will be concentrated by lyophilization in a Speed-Vac (Holten, Gydevang, Denmark) to about 0.1ml. CSF protein immunoblotting will be performed using a similar methodology as described above [and see also(Kozlovsky et al., 2004)]. Protein expression will be analyzed by western blots (Shiryaev et al., 2010). Number of patients: We estimate that about 30 patients with Alzheimer's disease, 20 patients with frontotemporal dementia and 20 controls will be included. Professor Aharon-Peretz will evaluate patients with suspected Alzheimer's disease and frontotemporal dementia and include patients at various disease stages in a stratified manner (mild, moderate and severe). All patients will have signed an informed consent form, as per Helsinki guidelines. Clinical evaluation will include: physical and neurological evaluation. All patients will be asked to donate 50 ml blood and selected patients will undergo lumber puncture. The lumber puncture will be performed with the neurological work up. Professor Gozes will coordinate the scientific aspect of the study. Study coordinators: Scientific: Professor Illana Gozes, PhD, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors; Director, The Adams Super Center for Brain Studies, Tel Aviv University: igozes@post.tau.ac.il Clinical material: Professor Judith Aharon-Peretz, MD, Head of "Cognitive Neurology Unit" Rambam Rambam-Health Care Campus, Haifa, Israel
3 schema:endDate 2014-01-01T00:00:00Z
4 schema:keywords AD
5 Alzheimer Disease
6 Alzheimer's
7 Amyloid Plaque
8 Assessing
9 Biological Marker
10 CSF
11 CSF sample
12 DNA
13 Denmark
14 Freeze Drying
15 Haifa
16 Israel
17 MD
18 PhD
19 Pick's
20 RNA
21 RNA extraction
22 RNA transcript
23 Real-Time Polymerase Chain Reaction
24 SDS-polyacrylamide gel electrophoresis
25 Specific aim
26 Tel Aviv
27 Western Blotting
28 Western analysis
29 absence
30 abundance
31 aphasia
32 assay
33 atrophy
34 blood
35 blood cell
36 brain study
37 cellular protein
38 chair
39 clinical evaluation
40 clinical material
41 cognitive dysfunction
42 comparison
43 consent form
44 control
45 corticobasal degeneration
46 dementia
47 depletion
48 determination
49 disease
50 disease progression
51 disease stage
52 dry ice
53 dysfunction
54 early detection
55 frontotemporal dementia
56 frontotemporal lobar degeneration
57 growth factor
58 guideline
59 half
60 head
61 human lymphocyte
62 ice
63 immunoblotting
64 immunodepletion
65 inclusion
66 investigator aim
67 lymphocyte
68 manuscript
69 marker
70 medicine
71 method
72 needle
73 neurodegeneration
74 neurology
75 patient
76 patient population
77 plasma
78 plasma protein
79 population
80 possibility
81 preparation
82 progressive supranuclear palsy
83 protein
84 protein expression
85 protein level
86 protein quantification
87 puncture
88 quantitation
89 reagent
90 recent publication
91 recognition
92 rock
93 scientific aspect
94 selected patient
95 serum
96 sigma
97 significance
98 similar methodology
99 speed
100 study coordinator
101 subsequent maintenance
102 syndrome
103 tangle
104 tau
105 tau pathology
106 tauopathies
107 venous blood
108 vertebral
109 schema:name Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized
110 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01403519
111 schema:sdDatePublished 2019-03-07T15:24
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher N33977b98a1444e16a47c6f7479c122fa
114 schema:sponsor https://www.grid.ac/institutes/grid.12136.37
115 https://www.grid.ac/institutes/grid.413731.3
116 schema:startDate 2011-07-01T00:00:00Z
117 schema:subjectOf sg:pub.10.1007/s00702-003-0127-0
118 https://doi.org/10.1002/jnr.22431
119 https://doi.org/10.1016/0022-1759(77)90120-x
120 https://doi.org/10.1016/0022-1759(82)90301-5
121 https://doi.org/10.1016/j.euroneuro.2010.06.004
122 https://doi.org/10.1016/j.neurobiolaging.2009.03.011
123 https://doi.org/10.2174/156720510793611628
124 schema:url https://clinicaltrials.gov/show/NCT01403519
125 sgo:license sg:explorer/license/
126 sgo:sdDataset clinical_trials
127 rdf:type schema:MedicalStudy
128 N33977b98a1444e16a47c6f7479c122fa schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 anzsrc-for:3120 schema:inDefinedTermSet anzsrc-for:
131 rdf:type schema:DefinedTerm
132 sg:pub.10.1007/s00702-003-0127-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047259725
133 https://doi.org/10.1007/s00702-003-0127-0
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1002/jnr.22431 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012508219
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1016/0022-1759(77)90120-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1016178552
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1016/0022-1759(82)90301-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043921516
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1016/j.euroneuro.2010.06.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023497938
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1016/j.neurobiolaging.2009.03.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047358633
144 rdf:type schema:CreativeWork
145 https://doi.org/10.2174/156720510793611628 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069189008
146 rdf:type schema:CreativeWork
147 https://www.grid.ac/institutes/grid.12136.37 schema:Organization
148 https://www.grid.ac/institutes/grid.413731.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...